Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A REMS by any Other Name

This article was originally published in RPM Report

Executive Summary

A new prescription drug for treatment of varicose veins clears FDA. The only dispute in the review: how to handle a remote but real risk of anaphylaxis. A REMS? Not this time…

You may also be interested in...

Making a Good First Impression: Launch Messages in an Era of REMS

When FDA took the unusual step of reprimanding a clinical investigator for promoting a newly approved botulinum toxin brand, the agency stressed its over-riding concern about the "first impression" of a new product in marketing messages Commercial sponsors should pay attention: just ask King.

FDAAA Impact (Year Two): More of Everything

The second year of the FDAAA-era is over, and FDA is using its new drug safety tools (Risk Evaluation & Mitigation Strategies and mandatory post-marketing studies) more often. Not only are more drugs requiring REMS and mandatory trials, the burden of those programs is increasing.

Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?

Provenge and pirfenidone were two of the most closely watched pending applications at FDA. The agency's decision on the two therapies may offer some insight into the current regulatory climate.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts